Navigation Links
Solos Endoscopy Finishes the 3rd Quarter Strong
Date:10/21/2011

BOSTON, Oct. 21, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company finished the 3rd Quarter strong with sales revenues during the three months ended September 30, 2011 in the amount of $86,717.40.  The revenue for the third quarter is a result of instrument sales to over sixty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos Breast Endoscopy component sales accounted for approximately 39.5% of the total sales revenue for the third quarter or $34,290. The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"We're proud of our efforts during the 3rd Quarter, and we anticipate continued sales growth as we finish out the year," stated Bob Segersten, President of Solos Endoscopy, Inc.

The Company recently announced its intentions to donate 5% of its sales from the MammoView® Breast Endoscopy Instrument line for the month of October to support breast cancer awareness through education and early detection. The Company expects to post its full unaudited financial results for the quarter ended September 30, 2011 on the OTC Markets Group website within in the next thirty days.

About Solos Endoscopy, Inc.:Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.CONTACT:

Amanda Segerstenrsegersten@solosendoscopy.com
'/>"/>

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
2. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
3. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
4. Solos Endoscopy to Reduce Debt by Over $620,000
5. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
6. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
7. Solos Endoscopy, Inc. To Launch New Corporate Website
8. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
9. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
10. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
11. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/26/2017)... ... 26, 2017 , ... Somnoware, a leading provider of digital ... its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device integration ... platform, initializing devices and importing studies are just one-click operations. This plugin streamlines ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... Peace Agreements being discussed by President Donald Trump and the rest of the world. ... speed up peace talks in the continuous battle between Israel and Palestine. The world’s ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
Breaking Medicine News(10 mins):